We use your email only to reply to you.
Principal on Sands Capital's Life Sciences Pulse strategy, investing in therapeutics; joined in 2022 as an associate after the Zurich venture fund OCCIDENT; holds a Ph.D. in neurotechnology from ETH Zurich.
Sands Capital